BOULDER, Colo.--(BUSINESS WIRE)--SomaLogic, Inc., announced today that Dan Muehl has joined the company as Chief Financial Officer (CFO). “I am delighted that Dan has agreed to join us during this critical growth period for SomaLogic,” said Byron Hewett, Chief Executive Officer. “His financial and personal skills are an ideal match for our culture and team, and for the challenging work ahead of us.”
“I am excited to join the SomaLogic team and to contribute to the continued success of their hard work over the past 14 years,” said Dan. “The tremendous potential of the powerful technology they have developed is unlike anything I have seen before, and I look forward to working with my new colleagues to seize the many opportunities before us.”
Dan joins SomaLogic with more than 28 years of financial management experience including CFO roles at three publicly traded technology growth companies. At SomaLogic, he will apply his expertise in finance and operations management, strategic partnering, financing, investor relations, compliance, and mergers and acquisitions to accelerate the company’s progress toward commercialization of new products and services and coordinating additional funding for continued growth. Prior to joining SomaLogic, Dan was CFO of bio-industrial company OPX Biotechnologies, where he closed $47 million in equity and debt financing; vice president of finance at bio-pharmaceutical company Pharmion (prior to its acquisition by Celgene); CFO at biotechnology company Repligen Corporation; CFO at medical device manufacturer Physiometrix Inc.; and CFO and chief operating officer at Number Nine Visual Technology, a computer graphics design and manufacturing company. Dan began his career in public accounting at Ernst & Young. He earned a B.S. in accounting from the University of Massachusetts – Amherst and received his CPA certificate in 1990.
Dan is taking over the CFO position from Scott Kothlow, who has chosen to step away from the role in order to focus on other business needs at SomaLogic. “All of us here are deeply indebted to Scott for his steadfast and strong financial leadership this past almost 14 years,” Said Byron Hewett. “We are also very happy that he will continue to be a part of SomaLogic, bringing his deep experience and insight to our continued efforts.”
SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, CO. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.